Media & Publications

PepGen attends BioTrinity in London

May 2, 2019

PepGen attended the BioTrinity conference from the 29th of April to the 1st of May 2019. The company was represented by Damian Marron (Chairman of the Board), Dr Caroline Godfrey (CEO) and Dr Sonia Bracegirdle (CBO) at this event. Alongside meetings with potential investors and partners, Dr Godfrey also presented PepGen’s pitch deck at the …

PepGen attends BioTrinity in London Read More »

PepGen’s £1.6M grant from Innovate UK has commenced

February 1, 2019

On the 1st of February 2019, PepGen’s £1.6M Innovate UK grant officially commenced. The company will initially focus on platform validation studies in small and large in vivo models, with project management and intellectual property workpackages running parallel to this experimental work. PepGen is excited to draw on the support of Innovate UK over the …

PepGen’s £1.6M grant from Innovate UK has commenced Read More »

PepGen receives a £1.6M grant from Innovate UK

November 2, 2018

PepGen has been awarded a grant of £1.6 M from Innovate UK, the UK’s innovation agency. The company’s project, entitled ‘Application of a novel peptide delivery platform to nucleic acid therapeutics in degenerative and rare diseases’, will run for 20 months, and this funding will be instrumental in supporting the pre-clinical development of PepGen’s innovative …

PepGen receives a £1.6M grant from Innovate UK Read More »

PepGen moves into new facilities

September 11, 2018

PepGen is the first tenant of the BioEscalator development in Oxford, having moved into new office and laboratory spaces at these premises on the 10th of September 2018. The BioEscalator was built to support early-stage life sciences companies in Oxford, and offers extensive shared facilities to tenants, including cold storage, tissue culture and chemistry equipment. …

PepGen moves into new facilities Read More »

PepGen has launched

March 27, 2018

On 26th March 2018 PepGen, a biotech company focused on the peptide-mediated delivery of nucleic acids, was spun out from the University of Oxford (OU) and the Medical Research Council (MRC). The intellectual property underpinning PepGen’s technology platform was developed through a decade-long collaboration between Professor Matthew Wood (OU) and Dr Michael Gait (MRC). The …

PepGen has launched Read More »

PepGen attends BioTrinity in London

PepGen attended the BioTrinity conference from the 29th of April to the 1st of May 2019. The company was represented by Damian Marron (Chairman of the Board), Dr Caroline Godfrey (CEO) and Dr Sonia Bracegirdle (CBO) at this event. Alongside meetings with potential investors and partners, Dr Godfrey also presented …

Read More

PepGen’s £1.6M grant from Innovate UK has commenced

On the 1st of February 2019, PepGen’s £1.6M Innovate UK grant officially commenced. The company will initially focus on platform validation studies in small and large in vivo models, with project management and intellectual property workpackages running parallel to this experimental work. PepGen is excited to draw on the support …

Read More

PepGen receives a £1.6M grant from Innovate UK

PepGen has been awarded a grant of £1.6 M from Innovate UK, the UK’s innovation agency. The company’s project, entitled ‘Application of a novel peptide delivery platform to nucleic acid therapeutics in degenerative and rare diseases’, will run for 20 months, and this funding will be instrumental in supporting the …

Read More

PepGen moves into new facilities

PepGen is the first tenant of the BioEscalator development in Oxford, having moved into new office and laboratory spaces at these premises on the 10th of September 2018. The BioEscalator was built to support early-stage life sciences companies in Oxford, and offers extensive shared facilities to tenants, including cold storage, …

Read More

PepGen has launched

On 26th March 2018 PepGen, a biotech company focused on the peptide-mediated delivery of nucleic acids, was spun out from the University of Oxford (OU) and the Medical Research Council (MRC). The intellectual property underpinning PepGen’s technology platform was developed through a decade-long collaboration between Professor Matthew Wood (OU) and …

Read More